Category Archives: TRIPS flexibilities

Why do new medicines cost so much, and what can we do about it?

  The cost of new drugs is putting increasing pressure on people in both rich and poor countries. We explain why it’s a burning issue by Sarah Boseley Health editor Why does it matter what medicines cost? If you are lucky enough … Continue reading

Posted in Doha Declaration, Patent, R&D, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

The Power of TRIPS Flexibilities in Medicines Procurement

Source: Medicine Law & Policy The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV).  Treatment will be a combination of antivirals (sofosbuvir and daclatasvir) from generic producers, including the Egyptian company … Continue reading

Posted in Compulsory Licensing, TRIPS flexibilities, Uncategorized | Leave a comment

MSF statement on resumption of EU-India FTA negotiations

Source: MSF Access Campaign | 11 April 2018 Officials from the European Union (EU) and India are expected to meet in Brussels on April 12th to resume technical talks on the long-stalled EU-India free trade agreement (FTA). A leaked draft … Continue reading

Posted in EU-India FTA, IPR, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

Time to explore the licence to make new TB drugs more accessible

By Leena Menghaney, The Hindu BusinessLine | March 16, 2018 The World Health Organization (WHO) estimates that tuberculosis (TB) prevalence is decreasing at a rate of about 2 per cent per year worldwide and that timely diagnosis and treatment have … Continue reading

Posted in Compulsory Licensing, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | Leave a comment

Indian civil society pushes for ‘Government Use’ compulsory license on MDR-TB Drugs

Source: Lawyers Collective | 12 March 2018 Survivors of drug resistant tuberculosis, health organisations and the TB community in India and across the globe have appealed to the Prime Minister of India to issue a government use compulsory license for … Continue reading

Posted in Compulsory Licensing, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | Leave a comment

Health bodies push for compulsory licence for two drugs on MDR-TB

Source: PTI Published: India Today | March 13, 2018 New Delhi: Survivors of drug-resistant tuberculosis, health organisations and the TB community have appealed to Prime Minister Narendra Modi to allow issuance of compulsory licence for two of the essential drugs … Continue reading

Posted in Compulsory Licensing, Patent, Tuberculosis (TB), Uncategorized | Leave a comment

Letter to India’s Prime Minister: Grant Compulsory License for Bedaquiline and Delaminid

DRUG ACTION FORUM – KARNATAKA 57, Tejaswinagar, Dharwad 580002. 0836-2461722 https://m.facebook.com/DrugActionForumKarnataka/ (Registered, independent NGO campaigning for Rational Drug Therapy and Policies) Date 9th March 2018 To, The Prime Minister, New Delhi. narendramodi1234@gmail.com Sir Subject;- Granting of CL for Bedaquiline and … Continue reading

Posted in Compulsory Licensing, Drug prices, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | 1 Comment